Therapeutic implications of activating noncanonical PIK3CA mutations in head and neck squamous cell carcinoma.

Saved in:
Bibliographic Details
Title: Therapeutic implications of activating noncanonical PIK3CA mutations in head and neck squamous cell carcinoma.
Authors: Jin N; Department of Otolaryngology, Head and Neck Surgery, University of California San Francisco, San Francisco, California, USA., Keam B; Department of Internal Medicine, Seoul National University Hospital, Seoul, South Korea., Cho J; Department of Otolaryngology, Head and Neck Surgery, University of California San Francisco, San Francisco, California, USA., Lee MJ; Department of Otolaryngology, Head and Neck Surgery, University of California San Francisco, San Francisco, California, USA., Kim HR; Division of Medical Oncology, Department of Internal Medicine, Yonsei University College of Medicine, Yonsei Cancer Center, Seoul, South Korea., Torosyan H; Cardiovascular Research Institute and., Jura N; Cardiovascular Research Institute and.; Department of Cellular and Molecular Pharmacology, University of California San Francisco, San Francisco, California, USA., Ng PK; Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.; The Jackson Laboratory for Genomic Medicine, Farmington, Connecticut, USA., Mills GB; Knight Cancer Institute, Oregon Health & Science University, Portland, Oregon, USA., Li H; Department of Otolaryngology, Head and Neck Surgery, University of California San Francisco, San Francisco, California, USA., Zeng Y; Department of Otolaryngology, Head and Neck Surgery, University of California San Francisco, San Francisco, California, USA., Barbash Z; NovellusDx, Jerusalem, Israel., Tarcic G; NovellusDx, Jerusalem, Israel., Kang H; Department of Medicine, University of California San Francisco, San Francisco, California, USA., Bauman JE; Department of Medicine, University of Arizona, Tucson, Arizona, USA., Kim MO; Department of Epidemiology and Biostatistics and., VanLandingham NK; Department of Otolaryngology, Head and Neck Surgery, University of California San Francisco, San Francisco, California, USA., Swaney DL; Department of Cellular and Molecular Pharmacology, University of California San Francisco, San Francisco, California, USA.; Quantitative Biosciences Institute (QBI), University of California San Francisco, San Francisco, California, USA.; J. David Gladstone Institutes, San Francisco, California, USA., Krogan NJ; Department of Cellular and Molecular Pharmacology, University of California San Francisco, San Francisco, California, USA.; Quantitative Biosciences Institute (QBI), University of California San Francisco, San Francisco, California, USA.; J. David Gladstone Institutes, San Francisco, California, USA., Johnson DE; Department of Otolaryngology, Head and Neck Surgery, University of California San Francisco, San Francisco, California, USA., Grandis JR; Department of Otolaryngology, Head and Neck Surgery, University of California San Francisco, San Francisco, California, USA.
Source: The Journal of clinical investigation [J Clin Invest] 2021 Nov 15; Vol. 131 (22).
Publication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
Journal Info: Publisher: American Society for Clinical Investigation Country of Publication: United States NLM ID: 7802877 Publication Model: Print Cited Medium: Internet ISSN: 1558-8238 (Electronic) Linking ISSN: 00219738 NLM ISO Abbreviation: J Clin Invest Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1558-8238
DOI:10.1172/JCI150335